Ask AI
Multidisciplinary Team in MBC Care
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Released: May 29, 2025

Expiration: November 28, 2025

Activity

Progress
1
Course Completed

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:

  • Key Comorbidities in Patients with HR+/HER2- MBC
  • Impact of Polypharmacy
  • Role of APPs in Comprehensive Care
  • Role of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBC
  • Utility of RWE data
  • Communicating Treatment Options With Patients and Caregivers
  • Understanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life